Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis

Biochemical and Biophysical Research Communications

Volumn 397, Issue 4, 2010, Pages 729-734

  Pourgholami, Mohammad H ^a   Khachigian, Levon M ^a   Fahmy, Roger G ^a   Badar, Samina ^a   Wang, Lisa ^a   Chu, Stephanie Wai Ling ^a   Morris, David Lawson ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Albendazole; Angiogenesis inhibitor; Bevacizumab; HUVEC; VEGF; VEGFR 2

Indexed keywords

ALBENDAZOLE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL MIGRATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION;

ALBENDAZOLE; ANGIOGENESIS INHIBITORS; ANIMALS; CAPILLARY PERMEABILITY; CELL MOVEMENT; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; INFANT, NEWBORN; MICE; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS;

EID: 77954385451     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.06.019     Document Type: Article

References (38)

1. Theodorides V.J., Gyurik R.J., Kingsbury W.D., Parish R.C. Anthelmintic activity of albendazole against liver flukes, tapeworms, lung and gastrointestinal roundworms 1976, 32:702-703.
2. Horton J. Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations. Curr. Opin. Infect. Dis. 2002, 15:599-608.
3. Fenton-Lee D., Morris D.L. The management of hydatid disease of the liver: Part 2. Trop. Doct. 1997, 27:87-88.
4. Borgers M., De Nollin S., De Brabander M., Thienpont D. Influence of the anthelmintic mebendazole on microtubules and intracellular organelle movement in nematode intestinal cells. Am J Vet Res 1975, 36:1153-1166.
5. Lacey E., Watson T.R. Structure-activity relationships of benzimidazole carbamates as inhibitors of mammalian tubulin. Biochem. Pharmacol. 1985, 34:1073-1077.
6. Pourgholami M.H., Woon L., Almajd R., Akhter J., Bowery P., Morris D.L. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett. 2001, 165:43-49.
7. Mukhopadhyay T., Sasaki J., Ramesh R., Roth J.A. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin. Cancer Res. 2002, 8:2963-2969.
8. Khalilzadeh A., Wangoo K.T., Morris D.L., Pourgholami M.H. Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: involvement of apoptotic pathways. Biochem. Pharmacol. 2007, 74:407-414.
9. Sasaki J., Ramesh R., Chada S., Gomyo Y., Roth J.A., Mukhopadhyay T. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol. Cancer Ther. 2002, 1:1201-1209.
10. Pourgholami M.H., Akhter J., Wang L., Lu Y., Morris D.L. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother. Pharmacol. 2005, 55:425-432.
11. Martarelli D., Pompei P., Baldi C., Mazzoni G. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother. Pharmacol. 2008, 61:809-817.
12. Pourgholami M.H., Cai Z.Y., Wang L., Badar S., Links M., Morris D.L. Morris, inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole. Cancer Invest. 2009, 27:171-177.
13. Pourgholami M.H., Cai Z.Y., Badar S., Wangoo K., Poruchynsky M.S., Morris D.L. Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole. BMC Cancer 2010, 10:143.
14. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 2002, 29:10-14.
15. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl. 3):4-10.
16. Ojima T., Takagi H., Suzuma K., Oh H., Suzuma I., Ohashi H., Watanabe D., Suganami E., Murakami T., Kurimoto M., Honda Y., Yoshimura N. EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am. J. Pathol. 2006, 168:331-339.
17. Papetti M., Herman I.M. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 2002, 282:C947-970.
18. Ciccarelli M., Santulli G., Campanile A., Galasso G., Cervero P., Altobelli G.G., Cimini V., Pastore L., Piscione F., Trimarco B., Iaccarino G. Endothelial alpha1-adrenoceptors regulate neo-angiogenesis. Br. J. Pharmacol. 2008, 153:936-946.
19. Bates D.O., Harper S.J. Regulation of vascular permeability by vascular endothelial growth factors. Vascul. Pharmacol. 2002, 39:225-237.
20. Awasthi N., Schwarz M.A., Verma V., Cappiello C., Schwarz R.E. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. Lab. Invest. 2009, 89:38-46.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
22. Rajesh M., Mukhopadhyay P., Batkai S., Godlewski G., Hasko G., Liaudet L., Pacher P. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem. Biophys. Res. Commun. 2006, 350:352-357.
23. Rajesh M., Mukhopadhyay P., Godlewski G., Batkai S., Hasko G., Liaudet L., Pacher P. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem. Biophys. Res. Commun. 2006, 350:1056-1062.
24. Chen J., Somanath P.R., Razorenova O., Chen W.S., Hay N., Bornstein P., Byzova T.V. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat. Med. 2005, 11:1188-1196.
25. Fahmy R.G., Waldman A., Zhang G., Mitchell A., Tedla N., Cai H., Geczy C.R., Chesterman C.N., Perry M., Khachigian L.M. Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nat. Biotechnol. 2006, 24:856-863.
26. Lal B.K., Varma S., Pappas P.J., Hobson R.W., Duran W.N. Duran, VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc. Res. 2001, 62:252-262.
27. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 2005, 333:328-335.
28. Karkkainen M.J., Petrova T.V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000, 19:5598-5605.
29. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 1994, 35:101-111.
30. Gariano R.F., Gardner T.W. Retinal angiogenesis in development and disease. Nature 2005, 438:960-966.
31. Pourgholami M.H., Yan Cai Z., Lu Y., Wang L., Morris D.L. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin. Cancer Res. 2006, 12:1928-1935.
32. Nagy J.A., Benjamin L., Zeng H., Dvorak A.M., Dvorak H.F. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008, 11:109-119.
33. Ettenson D.S., Gotlieb A.I. Centrosomes, microtubules, and microfilaments in the reendothelialization and remodeling of double-sided in vitro wounds. Lab. Invest. 1992, 66:722-733.
34. Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M.R., Viale G., Giavazzi R., Taraboletti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 1996, 2:1843-1849.
35. Vacca A., Iurlaro M., Ribatti D., Minischetti M., Nico B., Ria R., Pellegrino A., Dammacco F. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999, 94:4143-4155.
36. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
37. Meissner M., Pinter A., Michailidou D., Hrgovic I., Kaprolat N., Stein M., Holtmeier W., Kaufmann R., Gille J. Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanisms. J. Invest. Dermatol. 2008, 128:2084-2091.
38. Sun X., Vale M., Jiang X., Gupta R., Krissansen G.W. Antisense HIF-1alpha prevents acquired tumor resistance to angiostatin gene therapy. Cancer Gene Ther. 2010.